Sandoz Group AG (SWX:SDZ)
Switzerland · Delayed Price · Currency is CHF 46.73
-1.03 (-2.16%)
Jul 31, 2025, 5:31 PM CET
Sandoz Group AG Company Description
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology.
It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Sandoz Group AG
| Country | Switzerland |
| Founded | 1886 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 22,049 |
| CEO | Richard Saynor |
Contact Details
Address: Centralbahnstrasse 4 Basel, 4051 Switzerland | |
| Phone | 41 61 324 11 11 |
| Website | sandoz.com |
Stock Details
| Ticker Symbol | SDZ |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CH1243598427 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Saynor | Chief Executive Officer |
| Remco J. Steenbergen | Chief Financial Officer |
| Asaf Gal | Chief Technology Officer |
| Claire D'Abreu-Hayling | Chief Scientific Officer |
| Laurent de Weck | Head Investor Relations |
| Ingrid Sollerer | General Counsel and Chief Compliance Officer |
| Tripti Jha | Chief People Officer |
| Dr. Glenn A. Gerecke Ph.D. | Chief Manufacturing and Supply Officer |
| Rebecca Guntern | Chief Commercial Officer |
| Keren Haruvi | President of North America |